Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Age acceleration was significantly associated with sex, clinical diagnosis, and levels of eight plasma biomarkers, including P-tau217 levels.
-
52/100
Plasma phosphorylated-tau (p-tau) biomarkers show high performance as first-in-line tests in the evaluation of patients with cognitive symptoms and have also found utility in clinical trials for anti-amyloid drug therapies for Alzheimer's disease (AD).
-
Elevated CSF p-Tau181 and NfL levels were associated with greater decline in memory and executive function.
-
In the smallest required sample of 15 cAD and 10 Aβ-negative participants, conversion error was 1.7 Centiloids at 25 Centiloids and 3.4 Centiloids at 100 Centiloids.
-
CAA-PRS was significantly associated with pathological CAA (OR = 1.766, p < 0.001), with an AUC of 0.783 overall and 0.766 (OR = 1.780, p = 0.002) in those with high amyloid burden.
-
CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow-up studies.
-
In single predictor models, p-tau231 (AUC = 0.87, p = 0.005) and GFAP (AUC = 0.87, p = 0.01) were associated with amyloid positivity, and p-tau231 remained significant in all multi-predictor models (p-values < 0.02).
-
Accurate staging of Alzheimer's disease (AD) pathology is crucial for therapeutic trials and prognosis, but existing fluid biomarkers lack specificity, especially for assessing tau deposition severity, in amyloid-beta (Aβ)-positive patients.
-
Dementia blood biomarkers are becoming increasingly important.
-
Plasma p-tau217 and p-tau217/Aβ1-42 are effective diagnostic tools.
-
Heritability estimates were 16% for Aβ42/40, 42% for NfL, and 60% for GFAP.
-
β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance.
-
The specificity and positive predictive value (PPV) of HTS positivity (HTSpos) were the highest (amyloid PET: 0.930 and 0.870, tau PET: 0.944 and 0.957, respectively), while Cimp and Nimp had a high negative predictive value (NPV) for amyloid PET (negativity) (0.750 and 0.725).
-
Early imaging-based detection of acute ischemic stroke (AIS) has improved in the era of reperfusion therapy.
-
52/100
Plasma A+/T + individuals showed the highest levels of astrocyte reactivity, Aβ plaque, tau tangle, and axonal degeneration, and the lowest hippocampal volume and temporal-metaROI cortical thickness.
-
Elderly human brains are vulnerable to multiple proteinopathies, although each protein has a different transmission pathway.
-
CSF-to-plasma transition will open new avenues for molecular phenotyping of Alzheimer's disease (AD).
-
There is greater interest in amyloid biomarker for the diagnosis of Alzheimer disease (AD) with the recent Food and Drug Administration approval of amyloid-targeted therapy.
-
Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower Aβ42/40 (p = 0.06).
-
52/100
Plasma biomarkers have shown promising performance in research cohorts in discriminating between different stages of Alzheimer's disease (AD).
-
Phosphorylated tau 181 (p-tau181), phosphorylated tau 231 (p-tau231), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) concentrations were unchanged both when stored at +4°C and +18°C. Amyloid-β 40 (Aβ40) and amyloid-β 42 (Aβ42) concentrations were stable for 24 h at +4°C but declined when stored at +18°C for longer than 6 h. This decline did not affect the Aβ42/Aβ40 ratio.
-
Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia.
-
52/100
Plasma and CSF p-tau 217 had equivalent diagnostic performance for biomarker-defined AD.
-
We examined whether plasma p-tau181 and p-tau217 are specific biomarkers of pathologically confirmed Alzheimer's disease (AD).
-
52/100
Ninety-one eyes of AD patients and 53 eyes of patients with other dementias were included.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Steroid-responsive encephalopathy with a peculiar CSF biomarker profile in an 89-year-old man
- Risk Factors for β-Amyloid Deposition in Healthy Aging
- [Optical coherence tomography angiography in neuronal diseases : Preliminary findings]
- Dynamic Imaging Markers of ARIA-H Risk in the A4 Study: A Person-Interval Analysis of Current Lesion Burden and Recent Microhaemorrhage Activity
- Melanopsin retinal ganglion cell loss in Alzheimer disease
- Centiloid method evaluation for amyloid PET of subcortical vascular dementia
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis
- Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET
- Neurovascular Outer Retinal Degeneration in Presymptomatic Alzheimer’s Disease: An Oculomic Biomarker Study
- Altered Clearance and Amyloid-Related Imaging Abnormalities